Herpes simplex

IDENTIFYSENSORS BIOLOGICS REACHES BREAKTHROUGH SENSITIVITY LEVELS WITH NEW DIGITAL DIAGNOSTICS PLATFORM

Retrieved on: 
수요일, 12월 7, 2022
Genome, Stomach, HIV, RT-PCR, Lyme disease, Mobile, Rotavirus, Hepatitis, Patient, COVID, Gonorrhea, Research, Digital, PCR, Food, FDA, Yellow fever, COVID-19, RSV, Infection, MRSA, Vaccine, Pharmaceutical industry, Adenoviridae, Herpes simplex, Chlamydia, Dengue fever, Norovirus

CLEVELAND, Dec. 7, 2022 /PRNewswire/ -- IdentifySensors Biologics has completed preliminary clinical tests of positive COVID-19 samples using new graphene digital sensors, which demonstrate level-of-detection capabilities four times more sensitive than PCR tests.

Key Points: 
  • The samples were then diluted to the preliminary limit of detection of 200 copies per milliliter and retested using Check4.
  • The research demonstrates that infections, such as COVID, RSV and influenza, can soon be diagnosed well before patients develop symptoms, said IdentifySensors Biologics Cofounder and CEO Gregory Hummer M.D.
  • Digital graphene sensors inside the cartridges target conserved regions of the genome allowing for high sensitivity and specificity.
  • The company's technology has expanded into multiple industries and applications, such as pathogen diagnostics and testing for food contamination.

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Retrieved on: 
화요일, 11월 15, 2022
New England Biolabs, Growth, Technology, Board, Hepatitis B, Intention, Environment, Therapy, Forward-looking statement, Degenerative disease, View, Company, NGS, Herpes simplex, Terminology, Research, Multimedia, COVID-19, Nature, Roche Diagnostics, Commercial Operating System (COS), DNA sequencing, Diagnosis, Monkeypox, Vaccine, Malaria

LONDON, Nov. 15, 2022 /PRNewswire/ --Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.

Key Points: 
  • LONDON, Nov. 15, 2022 /PRNewswire/ --Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.
  • "We are thrilled to welcome Richard to our team," said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs.
  • As the Vice President of In Vitro Diagnostic Sales, Mr. Pallin will lead Virax's commercial team and lead the execution of the Company's go-to-market strategy.
  • Prior to joining Virax, Mr. Pallin was the Vice President of Global Commercial Operations of Omixon, Inc., a global transplantation diagnostic company dedicated to transitioning the human leukocyte antigen community to Next Generation Sequencing (NGS) technologies.

Monoclonal Antibody Diagnostic Reagent Global Market Report 2022: Extensive R&D Efforts to Develop Novel Therapies Driving Growth - ResearchAndMarkets.com

Retrieved on: 
화요일, 11월 8, 2022
Health, General Health, Diagnosis, Infection, Chinese cuisine, Antibody, American Cancer Society, Growth, Patient, Application, Hormone, CAGR, Degenerative disease, CFDA, Biomedical Research, Population, Survival, Cancer, HIV/AIDS, International Council, Harmonization, Hepatitis, COVID-19, Enzyme, ELISA, Fluorophore, Overalls, Ageing, IAVI, Prevalence, Herpes simplex, International, Sale, Conditional sentence, Chlamydia, Vaccine, Pharmaceutical industry, Neutralizing antibody

The "Monoclonal Antibody Diagnostic Reagent Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Tests and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoclonal Antibody Diagnostic Reagent Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Tests and Application" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of cancer & other chronic diseases, extensive R&D efforts to develop novel therapies, and the presence of a strong pipeline of drugs under trial are the major factors boosting the market growth.
  • Such factors are stimulating the uptake of mAbs, which is contributing to the monoclonal antibody diagnostic reagent market growth.
  • Based on application, the monoclonal antibody diagnostic reagent market is segmented into hormones diagnosis, tumor monitoring, virus detection, and others.

Global Infectious Diseases Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
화요일, 10월 25, 2022
Health, Infectious Diseases, Campylobacter jejuni, MRSA, SEC, Directory, Review, Yellow fever, Salmonella, Global Infectious Disease Epidemiology Network, Chapter Three, Chapter One, Respiratory syncytial virus, Orientation, Contract, RSV, Chapter Five, Research, Anthrax, FIV, Methicillin-resistant Staphylococcus aureus, Escherichia coli, Technology, Haemophilus influenzae, Common cold, HIV, Chapter Six, Foot, Chapter Two, Herpes simplex, Dengue fever, A-Z, Tetanus, Mycobacterium avium complex, Streptococcus, Clostridium difficile, Hepatitis A, Lyme disease, Chapter Four, Pseudomonas aeruginosa, African trypanosomiasis, Hyperlink, Helicobacter pylori, TB, Vaccine, Pharmaceutical industry, Haemophilus, West Nile virus, Infection, Tuberculosis, H1N1, Zika fever, Sepsis, Cytomegalovirus, Diphtheria, Malaria

The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 2,900 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2015.

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Retrieved on: 
수요일, 10월 26, 2022
Disease, Therapy, Pandemic, Growth, Virus, Diagnosis, Director, Immunity, Antibody, Patient, Monkeypox, Research, COVID-19, Technology, Immune system, Company, IVD, Degenerative disease, Board, Intention, Nature, Hepatitis B, Environment, Vaccination, HPV, Forward-looking statement, Terminology, Vaccine, Herpes simplex, Malaria

LONDON, Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year.

Key Points: 
  • LONDON, Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year.
  • The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit and will include specimens from 96 healthy volunteers1.
  • The first test being developed using the Virax Immune platform is for immunity related to COVID-19.
  • Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.

Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit

Retrieved on: 
화요일, 9월 20, 2022
Therapy, Human, COVID-19, Monkeypox virus, Varicella zoster virus, Intention, Nature, Company, Hepatitis B, Growth, Monkeypox, Environment, Forward-looking statement, Patient, Herpes simplex, Technology, CE, Terminology, Diagnosis, Degenerative disease, Board, Union, Skin, Multimedia, View, Vaccine, Malaria

LONDON, Sept. 20, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkeypox virus with results typically available in 15 minutes. It also serves as a valuable initial screening test for individuals that have been exposed to monkeypox infected patients or a high-risk environment. The specialized diagnostic kits can be found by contacting the company's sales representatives.

Key Points: 
  • LONDON, Sept. 20, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union.
  • The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkeypox virus with results typically available in 15 minutes.
  • Virax's Chairman of the Board and Chief Executive Officer, James Foster commented "I am very proud of our organization's ability to quickly bring this rapid antigen test kit to market to help combat the monkeypox outbreak.
  • The Monkeypox Virus Antigen Rapid Test Kits are used for in vitro qualitative detection of the monkeypox virus antigen in the oropharyngeal (throat) swabs and skin exudates of humans by colloidal gold immunochromatography.

Virax BioLabs Presents at H.C. Wainwright's 24th Annual Global Investment Conference

Retrieved on: 
월요일, 9월 12, 2022
Therapy, Lotte New York Palace Hotel, COVID-19, Interest, Intention, Nature, Company, Hepatitis B, Growth, Monkeypox, Environment, Forward-looking statement, Herpes simplex, Technology, Terminology, Diagnosis, Sustainability Accounting Standards Board, Degenerative disease, NASDAQ, Board, Biotechnology, Conference, Multimedia, CFA, View, Vaccine, Malaria

Session details are as follows:

Key Points: 
  • Session details are as follows:
    Date: September 12-14, 2022 at Lotte New York Palace Hotel, New York, NY
    Virax management will be available during the conference for one-on-one meetings.
  • Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats.
  • In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.
  • We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.

Virax Biolabs Group Limited to Present at H.C. Wainwright's 24th Annual Global Investment Conference in New York, NY

Retrieved on: 
화요일, 9월 6, 2022
COVID-19, Monkeypox, Technology, Interest, Director, Board, CFA, Diagnosis, Hepatitis B, Degenerative disease, Intention, Conference, Biotechnology, Therapy, Company, Lotte New York Palace Hotel, Herpes simplex, Terminology, Growth, Environment, Forward-looking statement, Nature, Vaccine, Malaria

Interested parties may schedule a one-on-one meeting via email from Maxim Jacobs, CFA at [email protected]

Key Points: 
  • Interested parties may schedule a one-on-one meeting via email from Maxim Jacobs, CFA at [email protected]
    Founded in 2013, Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.
  • Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats.
  • In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.
  • We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.

St. Luke's Infectious Disease Experts Call on Dentists to be Alert for Monkeypox

Retrieved on: 
월요일, 8월 15, 2022
Sores, Monkeypox, Herpes simplex, Multimedia, Medicine, University Health Network, Public health, Dentist, Palate, Fluid mechanics, Aphthous stomatitis, COVID, Myalgia, COVID 19, Throat, Trauma, Infection, Pachydactylus labialis, Mouth, Rash, American Dental Association, Man, Fever, Patient, COVID-19, Oral and maxillofacial surgery, Partner (business rank), Skin, Google, Network, DMD, Dental hygienist, Tongue, Disease, Vaccine, Dentistry, St Luke's

"Early recognition by all healthcare providers including dentists can potentially bring the spread of this disease to a halt."

Key Points: 
  • "Early recognition by all healthcare providers including dentists can potentially bring the spread of this disease to a halt."
  • Dr. Jahre said St. Luke's is calling on the dental community to be alert for monkeypox because Network doctors have begun seeing oral monkeypox symptoms.
  • Monkeypox is transmitted most commonly through direct contact with body fluids or lesions of the body of someone who has the disease.
  • Currently more than 95% of the monkeypox cases involve men who have sexual relations with men who have multiple sexual partners.

Virax Biolabs Introduces Monkeypox and Varicella-Zoster Viruses Real-Time PCR Detection Kit

Retrieved on: 
화요일, 7월 26, 2022
Patient, Orthopoxvirus, Diagnosis, Severe acute respiratory syndrome coronavirus 2, Environment, GLOBE, COVID-19, Human, Headache, Forward-looking statement, World, Weakness, Viral disease, Intention, Herpes simplex, Monkeypox, Public health, World Health Organization, Nature, Hepatitis B, Biotechnology, Boil, Technology, Disease, Company, Nasdaq, Serum, Therapy, Terminology, Face, Growth, Animal, PCR, WHO, Degenerative disease, Vaccine, Pharmaceutical industry, Malaria

London, United Kingdom, July 26, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (Virax or the Company) (Nasdaq: VRAX),an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today launched distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits in response to the worlds major Monkeypox outbreak.

Key Points: 
  • London, United Kingdom, July 26, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (Virax or the Company) (Nasdaq: VRAX),an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today launched distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits in response to the worlds major Monkeypox outbreak.
  • The test is intended to aid in the rapid diagnosis of Monkeypox and varicella-zoster viruses in human serum and lesion exudate specimens, providing a preliminary test result.
  • This PCR Detection Kit will assist in making earlier diagnoses which will help with patient treatment and management.
  • Founded in 2013, Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.